AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

Upcoming trial readouts

Estimated primary-completion dates sourced from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates: they can and do move as trials progress. Recent moves are listed under delayed readouts, and late-stage studies are listed by year.

Events

Phase 3 and phase 2/3 readouts for the next 18 months, in your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

Company

165 more; type to narrow.

3158 upcoming events · loading the full calendar

November 2026 (40)
ObicetrapibPhase 3
Est. primary completion 2026-11 · A. Menarini + NewAmsterdam Pharma + Tanabe Pharma Corporation · Atherosclerotic Cardiovascular Disease
NCT05202509 · CT.gov ↗
What to watch
Tirzepatide (Zepbound) · ZepboundPhase 3
Est. primary completion 2026-11 · Eli Lilly · Obesity
NCT06962280 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3
Est. primary completion 2026-11 · Bristol-Myers Squibb + Sichuan Baili Pharmaceutical · Nasopharyngeal Carcinoma
NCT06118333 · CT.gov ↗
What to watch
Docetaxel · TaxoterePhase 3
Est. primary completion 2026-11 · Sanofi · Nasopharyngeal Carcinoma
NCT06118333 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2026-11 · Cheplapharm Arzneimittel GmbH · Nasopharyngeal Carcinoma
NCT06118333 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2026-11 · Merck & Co. + Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Non-Small Cell Lung Cancer
NCT06448312 · CT.gov ↗
What to watch
Tirzepatide (Zepbound) · ZepboundPhase 3
Est. primary completion 2026-11 · Eli Lilly · Obesity
NCT06914895 · CT.gov ↗
What to watch
retatrutidePhase 3
Est. primary completion 2026-11 · Eli Lilly · Obesity
NCT06662383 · CT.gov ↗
What to watch
vidofludimus calciumPhase 3
Est. primary completion 2026-11 · Immunic, Inc. · Multiple Sclerosis
NCT05201638 · CT.gov ↗
What to watch
vidofludimus calciumPhase 3
Est. primary completion 2026-11 · Immunic, Inc. · Multiple Sclerosis
NCT05134441 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2026-11 · AbbVie · Atopic Dermatitis
NCT06389136 · CT.gov ↗
What to watch
dupilumab · DupixentPhase 3
Est. primary completion 2026-11 · Regeneron Pharmaceuticals + Sanofi · Atopic Dermatitis
NCT06389136 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-11 · BeOne Medicines · Non-Small Cell Lung Cancer
NCT06704620 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-11 · Eli Lilly · Non-Small Cell Lung Cancer
NCT06704620 · CT.gov ↗
What to watch
CadonilimabPhase 3
Est. primary completion 2026-11 · Akeso · Gastric and Gastroesophageal Junction Adenocarcinoma
NCT06341335 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2026-11 · Merck & Co. · High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
NCT04221035 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-11 · · Moderate to Severe Atopic Dermatitis
NCT06239311 · CT.gov ↗
What to watch
Abatacept · OrenciaPhase 3
Est. primary completion 2026-11 · Bristol-Myers Squibb · Rheumatoid Arthritis
NCT05428488 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2026-11 · · Steinert's Disease, Myotonic Dystrophy 1, Metformin
NCT05532813 · CT.gov ↗
What to watch
Tadalafil · AdcircaPhase 3
Est. primary completion 2026-11 · Eli Lilly + Nippon Shinyaku + United Therapeutics · Fontan Palliation
NCT05206955 · CT.gov ↗
What to watch
ZemprocitinibPhase 3
Est. primary completion 2026-11 · Lynk Pharmaceuticals + Simcere Pharmaceutical · Ankylosing Spondylitis
NCT07237568 · CT.gov ↗
What to watch
AvelumabPhase 3
Est. primary completion 2026-11-24 · Merck KGaA · Solid Tumors
NCT03815643 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3
Est. primary completion 2026-11-24 · Bristol-Myers Squibb + Zai Lab · Alzheimer's Disease
NCT06585787 · CT.gov ↗
What to watch
rilzabrutinibPhase 3
Est. primary completion 2026-11-25 · Sanofi · Immune Thrombocytopenia
NCT07216079 · CT.gov ↗
What to watch
Soficitinib (ICP-332)Phase 3
Est. primary completion 2026-11-25 · Beijing InnoCare Pharma Tech Co. · Atopic Dermatitis
NCT06775860 · CT.gov ↗
What to watch
NiraparibPhase 3
Est. primary completion 2026-11-26 · GlaxoSmithKline + Zai Lab · Neoplasms
NCT03981796 · CT.gov ↗
What to watch
DostarlimabPhase 3
Est. primary completion 2026-11-26 · GlaxoSmithKline · Endometrial Cancer
NCT03981796 · CT.gov ↗
What to watch
MT1013Phase 3
Est. primary completion 2026-11-26 · Everest Medicines (Beijing) Co., Ltd. + Shaanxi Micot Pharmaceutical Technology · Chronic Kidney Disease, Secondary Hyperparathyroidism
NCT07122401 · CT.gov ↗
What to watch
Rimegepant (Nurtec ODT) · Nurtec ODTPhase 3
Est. primary completion 2026-11-29 · Eisai + Pfizer · Migraine
NCT06641466 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-11-30 · · Acute Lymphoblastic Leukemia
NCT03020030 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-11-30 · · Acute Lymphoblastic Leukemia, Pediatric
NCT03020030 · CT.gov ↗
What to watch
AtezolizumabPhase 3
Est. primary completion 2026-11-30 · Chugai Pharma + Roche · Cancer
NCT03148418 · CT.gov ↗
What to watch
Nab-paclitaxelPhase 3
Est. primary completion 2026-11-30 · Bristol-Myers Squibb · Non-Small Cell Lung Cancer
NCT05429463 · CT.gov ↗
What to watch
SintilimabPhase 3
Est. primary completion 2026-11-30 · Innovent Biologics · Non-Small Cell Lung Cancer
NCT05429463 · CT.gov ↗
What to watch
Doravirine · PifeltroPhase 3
Est. primary completion 2026-11-30 · Merck & Co. · HIV
NCT04892654 · CT.gov ↗
What to watch
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)Phase 3
Est. primary completion 2026-11-30 · Shionogi + ViiV Healthcare · HIV
NCT04892654 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-11-30 · Eli Lilly · Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy
NCT06156514 · CT.gov ↗
What to watch
TaragarestrantPhase 3
Est. primary completion 2026-11-30 · InventisBio · HR+/HER2- Metastatic Breast Cancer
NCT06954961 · CT.gov ↗
What to watch
Ferric carboxymaltose · Injectafer / FerinjectPhase 3
Est. primary completion 2026-11-30 · Daiichi Sankyo + Vifor Pharma · Advanced Gastric Carcinoma
NCT05226169 · CT.gov ↗
What to watch
WD-890Phase 3
Est. primary completion 2026-11-30 · Ningbo/Zhejiang Wenda Pharma Technology Co. · Psoriasis
NCT07672561 · CT.gov ↗
What to watch
December 2026 (184)
PenpulimabPhase 3
Est. primary completion 2026-12 · Akeso + Chia Tai Tianqing Pharmaceutical Group · Hepatocellular Carcinoma
NCT04344158 · CT.gov ↗
What to watch
Donidalorsen · DawnzeraPhase 3
Est. primary completion 2026-12 · Ionis Pharmaceuticals + Otsuka Holdings + Theratechnologies · Hereditary Angioedema
NCT05392114 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2026-12 · Gilead Sciences · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT04639986 · CT.gov ↗
What to watch
Ruzaltatug rezetecanPhase 3
Est. primary completion 2026-12 · Jiangsu Hengrui Pharmaceuticals · Non-Small Cell Lung Cancer
NCT06671379 · CT.gov ↗
What to watch
Actinium (225Ac) oxodotreotidePhase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors …
NCT05477576 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb + Sichuan Baili Pharmaceutical · Small Cell Lung Cancer
NCT06500026 · CT.gov ↗
What to watch
Tamoxifen (Soltamox) · SoltamoxPhase 3
Est. primary completion 2026-12 · Mayne Pharma + Rosemont Pharmaceuticals · Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
AnastrozolePhase 3
Est. primary completion 2026-12 · ANI Pharmaceuticals, Inc. + AstraZeneca + Laboratoires Juvisé Pharmaceuticals · Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
LetrozolePhase 3
Est. primary completion 2026-12 · Novartis · Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
CulmerciclibPhase 3
Est. primary completion 2026-12 · Sino Biopharmaceutical · Breast Cancer
NCT05780567 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb + Sichuan Baili Pharmaceutical · Non-Small Cell Lung Cancer
NCT06382129 · CT.gov ↗
What to watch
Docetaxel · TaxoterePhase 3
Est. primary completion 2026-12 · Sanofi · Non-Small Cell Lung Cancer
NCT06382129 · CT.gov ↗
What to watch
DurvalumabPhase 3
Est. primary completion 2026-12 · AstraZeneca · Oropharyngeal Cancer
NCT04116047 · CT.gov ↗
What to watch
TinengotinibPhase 3
Est. primary completion 2026-12 · TransThera Sciences (Nanjing), Inc. · Cholangiocarcinoma
NCT05948475 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-12 · Merck & Co. · Non-Small Cell Lung Cancer
NCT06711900 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2026-12 · Merck & Co. + Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Non-Small Cell Lung Cancer
NCT06711900 · CT.gov ↗
What to watch
Resmetirom · RezdiffraPhase 3
Est. primary completion 2026-12 · Madrigal Pharmaceuticals · MASH / NASH
NCT05500222 · CT.gov ↗
What to watch
Tobevibart (VIR-3434)Phase 3
Est. primary completion 2026-12 · Brii Biosciences + Norgine + Vir Biotechnology · Chronic Hepatitis Delta
NCT07128550 · CT.gov ↗
What to watch
RelutriginePhase 3
Est. primary completion 2026-12 · Praxis Precision Medicines, Inc. · Epilepsy, Developmental and Epileptic Encephalopathies
NCT07010471 · CT.gov ↗
What to watch
lutikizumabPhase 3
Est. primary completion 2026-12 · AbbVie · Hidradenitis Suppurativa
NCT06468228 · CT.gov ↗
What to watch
Palbociclib · IbrancePhase 3
Est. primary completion 2026-12 · Pfizer · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT03820830 · CT.gov ↗
What to watch
CetuximabPhase 3
Est. primary completion 2026-12 · Eli Lilly + Merck KGaA · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2026-12 · Bristol-Myers Squibb + Ono Pharmaceutical · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
BinimetinibPhase 3
Est. primary completion 2026-12 · Ono Pharmaceutical + Pfizer + Pierre Fabre Medicament · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
EncorafenibPhase 3
Est. primary completion 2026-12 · Ono Pharmaceutical + Pfizer + Pierre Fabre Medicament · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
PertuzumabPhase 3
Est. primary completion 2026-12 · Roche · Metastatic Colon Cancer, Stage III Colon Cancer
NCT03803553 · CT.gov ↗
What to watch
MasupirdinePhase 3
Est. primary completion 2026-12 · Suven Life Sciences · Alzheimer's Disease
NCT05397639 · CT.gov ↗
What to watch
SHR-1819Phase 3
Est. primary completion 2026-12 · Jiangsu Hengrui Pharmaceuticals · Seasonal Allergic Rhinitis
NCT07688772 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2026-12 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Obesity
NCT06994650 · CT.gov ↗
What to watch
viloxazine · QelbreePhase 3
Est. primary completion 2026-12 · Knight Therapeutics + M8 Pharmaceuticals + Supernus Pharmaceuticals · Attention Deficit Hyperactivity Disorder
NCT02736656 · CT.gov ↗
What to watch
RalinepagPhase 3
Est. primary completion 2026-12 · United Therapeutics · Pulmonary Arterial Hypertension
NCT03683186 · CT.gov ↗
What to watch
difamilast · Moizerto / AdqueyPhase 3
Est. primary completion 2026-12 · Acrotech Biopharma + Otsuka Holdings · Atopic Dermatitis
NCT07173478 · CT.gov ↗
What to watch
SeralutinibPhase 3
Est. primary completion 2026-12 · Gossamer Bio · Pulmonary Arterial Hypertension
NCT06274801 · CT.gov ↗
What to watch
SintilimabPhase 3
Est. primary completion 2026-12 · Innovent Biologics · Gastric Cancer
NCT05918094 · CT.gov ↗
What to watch
Lumateperone · CaplytaPhase 3
Est. primary completion 2026-12 · Intra-Cellular Therapies + Johnson & Johnson · Schizophrenia
NCT06482554 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12 · Roche · Non-Small Cell Lung Cancer
NCT05654454 · CT.gov ↗
What to watch
NiraparibPhase 3
Est. primary completion 2026-12 · GlaxoSmithKline + Zai Lab · Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
NCT03903835 · CT.gov ↗
What to watch
CapivasertibPhase 3
Est. primary completion 2026-12 · Astex Pharmaceuticals, Inc. + AstraZeneca · Prostate Cancer
NCT03903835 · CT.gov ↗
What to watch
Docetaxel · TaxoterePhase 3
Est. primary completion 2026-12 · Sanofi · Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer
NCT03903835 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-12 · Eli Lilly · Non-Small Cell Lung Cancer
NCT06754644 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12 · BeOne Medicines · Nasopharyngeal Carcinoma
NCT06177301 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2026-12 · · Type 2 Diabetes
NCT07093476 · CT.gov ↗
What to watch
Alogliptin · NesinaPhase 3
Est. primary completion 2026-12 · Takeda Pharmaceutical Company + Teijin · Type 2 Diabetes
NCT07093476 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2026-12 · Boehringer Ingelheim + Eli Lilly · Type 2 Diabetes
NCT07093476 · CT.gov ↗
What to watch
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)Phase 3
Est. primary completion 2026-12 · Shionogi + ViiV Healthcare · HIV
NCT06747507 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2026-12 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Obesity
NCT06974851 · CT.gov ↗
What to watch
apremilast · OtezlaPhase 3
Est. primary completion 2026-12 · Amgen · Recurrent Aphtous Stomatitis
NCT04227314 · CT.gov ↗
What to watch
IvonescimabPhase 3
Est. primary completion 2026-12 · Akeso + Summit Therapeutics · Triple-Negative Breast Cancer (TNBC)
NCT06767527 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2026-12 · AbbVie · Long COVID
NCT06928272 · CT.gov ↗
What to watch
Pirfenidone (Esbriet) · EsbrietPhase 3
Est. primary completion 2026-12 · Legacy Pharma Inc. SEZC + Roche · Long COVID
NCT06928272 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2026-12 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Nasopharyngeal Carcinoma
NCT05340491 · CT.gov ↗
What to watch
Semaglutide (Ozempic) · OzempicPhase 3
Est. primary completion 2026-12 · Novo Nordisk · Type 2 Diabetes
NCT07059377 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-12 · · Cardiac Sarcoidosis, Sarcoidosis
NCT03593759 · CT.gov ↗
What to watch
Solriamfetol · SunosiPhase 3
Est. primary completion 2026-12 · Axsome Therapeutics + Pharmanovia + SK Biopharmaceuticals Co., Ltd. · Excessive Sleepiness, Shift-work Disorder
NCT06568367 · CT.gov ↗
What to watch
Solriamfetol · SunosiPhase 3
Est. primary completion 2026-12 · Axsome Therapeutics + Pharmanovia + SK Biopharmaceuticals Co., Ltd. · Binge-Eating Disorder
NCT06413433 · CT.gov ↗
What to watch
ElsunersenPhase 3
Est. primary completion 2026-12 · Ionis Pharmaceuticals + Praxis Precision Medicines, Inc. · Epilepsy
NCT07019922 · CT.gov ↗
What to watch
FurmonertinibPhase 3
Est. primary completion 2026-12 · Allist Pharmaceuticals + ArriVent BioPharma · Non-small Cell Lung Carcinoma
NCT04853342 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12 · Roche · Ovarian Cancer
NCT05281471 · CT.gov ↗
What to watch
Olvimulogene nanivacirepvecPhase 3
Est. primary completion 2026-12 · Genelux Corporation + Newsoara HYK Biopharmaceuticals Co., Ltd. · Ovarian Cancer
NCT05281471 · CT.gov ↗
What to watch
stapokibartPhase 3
Est. primary completion 2026-12 · Aeira Pte. Ltd. + CSPC ZhongQi Pharmaceutical Technology Co., Ltd. + Keymed Biosciences · Seasonal Allergic Rhinitis (SAR)
NCT07678931 · CT.gov ↗
What to watch
DurvalumabPhase 3
Est. primary completion 2026-12 · AstraZeneca · Non-Small Cell Lung Cancer
NCT04585490 · CT.gov ↗
What to watch
TremelimumabPhase 3
Est. primary completion 2026-12 · AstraZeneca + MedImmune LLC · Non-Small Cell Lung Cancer
NCT04585490 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-12 · Eli Lilly · Non-Small Cell Lung Cancer
NCT04585490 · CT.gov ↗
What to watch
FelzartamabPhase 3
Est. primary completion 2026-12-01 · Biogen · Antibody-mediated Rejection
NCT06685757 · CT.gov ↗
What to watch
RAY1225Phase 3
Est. primary completion 2026-12-01 · Guangdong Raynovent Biotech + Qilu Pharmaceutical · Type 2 Diabetes
NCT07139548 · CT.gov ↗
What to watch
RAY1225Phase 3
Est. primary completion 2026-12-01 · Guangdong Raynovent Biotech + Qilu Pharmaceutical · Type 2 Diabetes
NCT07139535 · CT.gov ↗
What to watch
tradipitantPhase 3
Est. primary completion 2026-12-01 · Vanda Pharmaceuticals · Nausea and Vomiting, Obesity
NCT07446439 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2026-12-01 · AbbVie + Roche · Acute Myeloid Leukemia
NCT07712848 · CT.gov ↗
What to watch
CetuximabPhase 3
Est. primary completion 2026-12-01 · Eli Lilly + Merck KGaA · Head and Neck Squamous Cell Carcinoma
NCT06998069 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-12-01 · Merck & Co. · Head and Neck Squamous Cell Carcinoma
NCT06998069 · CT.gov ↗
What to watch
PF-06651600Phase 3
Est. primary completion 2026-12-02 · Pfizer · Severe Alopecia Areata
NCT07029711 · CT.gov ↗
What to watch
AnakinraPhase 3
Est. primary completion 2026-12-04 · Swedish Orphan Biovitrum AB (publ) · FMF
NCT06336733 · CT.gov ↗
What to watch
PF-07307405Phase 3
Est. primary completion 2026-12-04 · Pfizer · Lyme Disease
NCT07500506 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-06 · · Nausea and Vomiting Caused by Chemotherapy
NCT07716176 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-06 · · Nausea and Vomiting Caused by Trastuzumab Deruxtecan
NCT07716189 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-06 · · Nausea and Vomiting Caused by Chemotherapy
NCT07716228 · CT.gov ↗
What to watch
Eculizumab · SolirisPhase 3
Est. primary completion 2026-12-07 · Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) · NMOSD, Neuromyelitis Optica Spectrum Disorders
NCT06724809 · CT.gov ↗
What to watch
MilvexianPhase 3
Est. primary completion 2026-12-08 · Bristol-Myers Squibb + Johnson & Johnson · Atrial Fibrillation
NCT05757869 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3
Est. primary completion 2026-12-09 · Bristol-Myers Squibb + Zai Lab · Alzheimer's Disease
NCT06126224 · CT.gov ↗
What to watch
Zongertinib · HernexeosPhase 3
Est. primary completion 2026-12-10 · Boehringer Ingelheim · Non-Small Cell Lung Cancer
NCT06151574 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 3
Est. primary completion 2026-12-12 · AstraZeneca · Non-Small Cell Lung Cancer
NCT07376382 · CT.gov ↗
What to watch
CPO301Phase 3
Est. primary completion 2026-12-12 · Conjupro Biotherapeutics, Inc. · Non-Small Cell Lung Cancer
NCT07376382 · CT.gov ↗
What to watch
ivarmacitinibPhase 3
Est. primary completion 2026-12-13 · Jiangsu Hengrui Pharmaceuticals + Reistone Biopharma · Psoriatic Arthritis
NCT04957550 · CT.gov ↗
What to watch
crisaborole · EucrisaPhase 3
Est. primary completion 2026-12-13 · Pfizer · Psoriasis, Psoriasis Genital
NCT07892339 · CT.gov ↗
What to watch
Abp 234Phase 3
Est. primary completion 2026-12-14 · Amgen · Non-Small Cell Lung Cancer
NCT06430866 · CT.gov ↗
What to watch
AtezolizumabPhase 3
Est. primary completion 2026-12-15 · Chugai Pharma + Roche · Invasive Breast Cancer
NCT03595592 · CT.gov ↗
What to watch
PertuzumabPhase 3
Est. primary completion 2026-12-15 · Roche · Breast Cancer
NCT03595592 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2026-12-15 · Bristol-Myers Squibb + Ono Pharmaceutical · Renal Cell Carcinoma
NCT05678673 · CT.gov ↗
What to watch
ZanzalintinibPhase 3
Est. primary completion 2026-12-15 · Exelixis · Renal Cell Carcinoma
NCT05678673 · CT.gov ↗
What to watch
Cariprazine (Vraylar) · VraylarPhase 3
Est. primary completion 2026-12-15 · AbbVie + Gedeon Richter + Tanabe Pharma Corporation · Schizophrenia
NCT03817502 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2026-12-15 · Merck & Co. · Neuroblastoma (NB), Ganglioneuroblastoma
NCT07375563 · CT.gov ↗
What to watch
N-acetylcysteinePhase 3
Est. primary completion 2026-12-15 · Apotex Inc. + Phebra Pty Ltd · Psychosis
NCT05796401 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-15 · · Hospital Acquired Pneumonia
NCT06269900 · CT.gov ↗
What to watch
Gefurulimab · KlygefaPhase 3
Est. primary completion 2026-12-15 · AstraZeneca · Generalized Myasthenia Gravis
NCT06607627 · CT.gov ↗
What to watch
Docetaxel (HB1801)Phase 3
Est. primary completion 2026-12-16 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · HER2-Positive Breast Cancer
NCT06747338 · CT.gov ↗
What to watch
Elafibranor · IqirvoPhase 3
Est. primary completion 2026-12-17 · Genfit + Ipsen · Primary Biliary Cholangitis
NCT06730061 · CT.gov ↗
What to watch
Oveporexton · OrzeyfulPhase 3
Est. primary completion 2026-12-17 · Takeda Pharmaceutical Company · Narcolepsy
NCT07363720 · CT.gov ↗
What to watch
bimekizumab · BimzelxPhase 3
Est. primary completion 2026-12-21 · UCB · Hidradenitis Suppurativa
NCT06921850 · CT.gov ↗
What to watch
Ixoberogene soroparvovecPhase 3
Est. primary completion 2026-12-22 · Eli Lilly · Wet Age-Related Macular Degeneration
NCT06856577 · CT.gov ↗
What to watch
Suzetrigine · JournavxPhase 3
Est. primary completion 2026-12-22 · Vertex Pharmaceuticals · Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain
NCT07539623 · CT.gov ↗
What to watch
Benralizumab · FasenraPhase 3
Est. primary completion 2026-12-23 · AstraZeneca + Kyowa Kirin + MedImmune LLC · Asthma
NCT05692180 · CT.gov ↗
What to watch
VemurafenibPhase 3
Est. primary completion 2026-12-24 · Roche · Colorectal Cancer Metastatic
NCT06008119 · CT.gov ↗
What to watch
Trelagliptin · ZafatekPhase 3
Est. primary completion 2026-12-26 · Takeda Pharmaceutical Company + Teijin · Type 2 Diabetes
NCT07073768 · CT.gov ↗
What to watch
CarfilzomibPhase 3
Est. primary completion 2026-12-28 · Amgen + Ono Pharmaceutical · Multiple Myeloma
NCT03729804 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2026-12-28 · Janssen + Takeda Pharmaceutical Company · Multiple Myeloma
NCT03729804 · CT.gov ↗
What to watch
LenalidomidePhase 3
Est. primary completion 2026-12-28 · Bristol-Myers Squibb + Celgene Corporation · Multiple Myeloma
NCT03729804 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-28 · · Multiple Myeloma
NCT03729804 · CT.gov ↗
What to watch
TH-SC01Phase 3
Est. primary completion 2026-12-28 · Jiangsu Topcel-KH Pharmaceutical · Crohn's Disease
NCT06925594 · CT.gov ↗
What to watch
Olanzapine (Zyprexa) · ZyprexaPhase 3
Est. primary completion 2026-12-28 · Cheplapharm Arzneimittel GmbH + Eli Lilly · Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
NCT07633236 · CT.gov ↗
What to watch
Palbociclib · IbrancePhase 3
Est. primary completion 2026-12-30 · Pfizer · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT05909397 · CT.gov ↗
What to watch
Vepdegestrant · VeppanuPhase 3
Est. primary completion 2026-12-30 · Arvinas Inc. + Pfizer + Rigel Pharmaceuticals · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT05909397 · CT.gov ↗
What to watch
SintilimabPhase 3
Est. primary completion 2026-12-30 · Innovent Biologics · Colorectal Cancer Stage IV
NCT05171660 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12-30 · Roche · Colorectal Cancer, Metastatic Colorectal Cancer
NCT05171660 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2026-12-30 · Cheplapharm Arzneimittel GmbH · Colorectal Cancer, Metastatic Colorectal Cancer
NCT05171660 · CT.gov ↗
What to watch
Descartes-08Phase 3
Est. primary completion 2026-12-30 · Cartesian Therapeutics, Inc. · Myasthenia Gravis
NCT06799247 · CT.gov ↗
What to watch
CetrelimabPhase 3
Est. primary completion 2026-12-30 · Johnson & Johnson · Bladder Cancer
NCT04658862 · CT.gov ↗
What to watch
TAK-921Phase 3
Est. primary completion 2026-12-30 · Takeda Pharmaceutical Company · Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06238843 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2026-12-30 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Non-Small Cell Lung Cancer
NCT04772287 · CT.gov ↗
What to watch
Anbenitamab repodatecanPhase 3
Est. primary completion 2026-12-30 · Alphamab Oncology + CSPC Pharmaceutical Group · Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers
NCT06751485 · CT.gov ↗
What to watch
Sodium zirconium cyclosilicate · LokelmaPhase 3
Est. primary completion 2026-12-30 · AstraZeneca · Chronic Kidney Disease
NCT06578078 · CT.gov ↗
What to watch
SumecigrelPhase 3
Est. primary completion 2026-12-30 · Everest Medicines (Beijing) Co., Ltd. + Jiangsu Vcare Pharmaceutical Technology Co., Ltd. · Atherosclerotic Cardiovascular Disease
NCT06577519 · CT.gov ↗
What to watch
SeltorexantPhase 3
Est. primary completion 2026-12-30 · Johnson & Johnson · Major Depressive Disorder
NCT06559306 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · Gastric Cancer
NCT06939439 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3
Est. primary completion 2026-12-31 · Glenmark Pharmaceuticals Ltd. + Jiangsu Hengrui Pharmaceuticals · Breast Cancer
NCT05424835 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12-31 · Eli Lilly · Hepatoblastoma, Carcinoma, Hepatocellular
NCT03017326 · CT.gov ↗
What to watch
mazdutidePhase 3
Est. primary completion 2026-12-31 · Eli Lilly + Innovent Biologics · Obesity
NCT06884293 · CT.gov ↗
What to watch
AlmonertinibPhase 3
Est. primary completion 2026-12-31 · Glenmark Pharmaceuticals Ltd. + Hansoh Pharmaceutical Group · Non-Small Cell Lung Cancer
NCT04841811 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2026-12-31 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Advanced Hepatocellular Carcinoma (HCC)
NCT04523493 · CT.gov ↗
What to watch
Migalastat · GalafoldPhase 3
Est. primary completion 2026-12-31 · Amicus Therapeutics + BioMarin Pharmaceutical · Fabry Disease
NCT04020055 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · B-cell Malignancies
NCT04170283 · CT.gov ↗
What to watch
zanubrutinib · BrukinsaPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · B-cell Malignancies
NCT04170283 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2026-12-31 · Merck & Co. · Glioma
NCT00978458 · CT.gov ↗
What to watch
CarfilzomibPhase 3
Est. primary completion 2026-12-31 · Amgen + Ono Pharmaceutical · Multiple Myeloma
NCT01863550 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2026-12-31 · Janssen + Takeda Pharmaceutical Company · Multiple Myeloma
NCT01863550 · CT.gov ↗
What to watch
LenalidomidePhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb + Celgene Corporation · Multiple Myeloma
NCT01863550 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-31 · · Plasma Cell Myeloma
NCT01863550 · CT.gov ↗
What to watch
Lecanemab · LeqembiPhase 3
Est. primary completion 2026-12-31 · Biogen + Eisai · Alzheimer's Disease
NCT03887455 · CT.gov ↗
What to watch
LorlatinibPhase 3
Est. primary completion 2026-12-31 · Pfizer · Non-Small Cell Lung Cancer
NCT05059522 · CT.gov ↗
What to watch
AvelumabPhase 3
Est. primary completion 2026-12-31 · Merck KGaA · Urothelial Carcinoma
NCT05059522 · CT.gov ↗
What to watch
AxitinibPhase 3
Est. primary completion 2026-12-31 · Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
NCT05059522 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2026-12-31 · Eli Lilly · Non-Small Cell Lung Cancer
NCT05059522 · CT.gov ↗
What to watch
TalazoparibPhase 3
Est. primary completion 2026-12-31 · Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
NCT05059522 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-12-31 · Merck & Co. · Non-Small Cell Lung Cancer
NCT07162883 · CT.gov ↗
What to watch
BexicaserinPhase 3
Est. primary completion 2026-12-31 · H. Lundbeck · Epilepsy
NCT06660394 · CT.gov ↗
What to watch
IbrutinibPhase 3
Est. primary completion 2026-12-31 · AbbVie + Johnson & Johnson · Diffuse Large B-Cell Lymphoma, Graft-versus-Host Disease, Chronic Graft-versus-Host Disease, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
NCT01804686 · CT.gov ↗
What to watch
RademikibartPhase 3
Est. primary completion 2026-12-31 · Connect Biopharma + Simcere Pharmaceutical · Asthma
NCT06488755 · CT.gov ↗
What to watch
VicadrostatPhase 3
Est. primary completion 2026-12-31 · Boehringer Ingelheim · Chronic Kidney Disease
NCT06531824 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2026-12-31 · Merck & Co. · Merkel Cell Carcinoma
NCT03712605 · CT.gov ↗
What to watch
FluzoparibPhase 3
Est. primary completion 2026-12-31 · Jiangsu Hengrui Pharmaceuticals · Metastatic Castration-Resistant Prostate Cancer
NCT04691804 · CT.gov ↗
What to watch
DurvalumabPhase 3
Est. primary completion 2026-12-31 · AstraZeneca · Cancer
NCT05303532 · CT.gov ↗
What to watch
HRS-9190Phase 3
Est. primary completion 2026-12-31 · Jiangsu Hengrui Pharmaceuticals · Adult Participants Requiring Tracheal Intubation Under General Anesthesia for Elective Surgery
NCT07733245 · CT.gov ↗
What to watch
ChidamidePhase 3
Est. primary completion 2026-12-31 · Chipscreen Biosciences + GNT Biotech & Medicals + HUYABIO International, LLC. + Meiji Seika Pharma + Nizhpharm · Extranodal Natural Killer T Cell Lymphoma
NCT06255795 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2026-12-31 · AbbVie · Crohn's Disease
NCT07149467 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2026-12-31 · AbbVie + Roche · Acute Myeloid Leukemia
NCT07486479 · CT.gov ↗
What to watch
AzacitidinePhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb · Acute Myeloid Leukemia
NCT07486479 · CT.gov ↗
What to watch
S-1Phase 3
Est. primary completion 2026-12-31 · Nordic Group B.V. + Taiho Pharmaceutical · Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect
NCT05813015 · CT.gov ↗
What to watch
Docetaxel · TaxoterePhase 3
Est. primary completion 2026-12-31 · Sanofi · Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect
NCT05813015 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2026-12-31 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Urothelial Carcinoma, HER2-expressing
NCT05302284 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3
Est. primary completion 2026-12-31 · Pfizer + RemeGen Co., Ltd. · Urothelial Carcinoma
NCT05302284 · CT.gov ↗
What to watch
CetuximabPhase 3
Est. primary completion 2026-12-31 · Eli Lilly + Merck KGaA · Metastatic Colorectal Cancer
NCT06226857 · CT.gov ↗
What to watch
Nab-paclitaxelPhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb · Glioma
NCT06330337 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2026-12-31 · Merck & Co. · Glioma
NCT06330337 · CT.gov ↗
What to watch
AzacitidinePhase 3
Est. primary completion 2026-12-31 · Bristol-Myers Squibb · Acute Myeloid Leukemia
NCT06345365 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2026-12-31 · Eli Lilly · Cervical Cancer, Cervix Cancer, Cervix Neoplasm
NCT05764044 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2026-12-31 · · Hodgkin Lymphoma, Adult
NCT04638790 · CT.gov ↗
What to watch
CamrelizumabPhase 3
Est. primary completion 2026-12-31 · Elevar Therapeutics, Inc. + Jiangsu Hengrui Pharmaceuticals · Triple-negative Breast Cancer
NCT06533384 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2026-12-31 · Cheplapharm Arzneimittel GmbH · Triple-negative Breast Cancer
NCT06533384 · CT.gov ↗
What to watch
FurmonertinibPhase 3
Est. primary completion 2026-12-31 · Allist Pharmaceuticals + ArriVent BioPharma · Non-Small Cell Lung Cancer
NCT06674343 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2026-12-31 · AstraZeneca + Ono Pharmaceutical · Heart Failure
NCT06304857 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2026-12-31 · BeOne Medicines · Advanced Cholangiocarcinoma
NCT05823311 · CT.gov ↗
What to watch
SC0062Phase 3
Est. primary completion 2026-12-31 · BioCity Biopharmaceutics · Chronic Kidney Disease
NCT06819826 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2026-12-31 · AbbVie + Roche · Acute Myeloid Leukemia
NCT06990321 · CT.gov ↗
What to watch
Azvudine · FNCPhase 3
Est. primary completion 2026-12-31 · Henan Genuine Biotech · Chronic Hepatitis B, Azvudine
NCT07307586 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2026-12-31 · Boehringer Ingelheim + Eli Lilly · Heart Failure
NCT05392764 · CT.gov ↗
What to watch
MethotrexatePhase 3
Est. primary completion 2026-12-31 · · T-cell Lymphoblastic Lymphoma
NCT05681260 · CT.gov ↗
What to watch
TelitaciceptPhase 3
Est. primary completion 2026-12-31 · RemeGen Co., Ltd. + Vor Bio · Myasthenia Gravis, Ocular
NCT07249632 · CT.gov ↗
What to watch
MethylprednisolonePhase 3
Est. primary completion 2026-12-31 · Pfizer · Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
NCT05058287 · CT.gov ↗
What to watch
Icosapent Ethyl · VascepaPhase 3
Est. primary completion 2026-12-31 · Amarin Corporation + Recordati · Inflammation, Community Acquired Pneumonia (CAP), Inflammation Plaque, Atherosclerotic
NCT06710080 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2026-12-31 · Merck & Co. + Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT06081959 · CT.gov ↗
What to watch
Eculizumab · SolirisPhase 3
Est. primary completion 2026-12-31 · Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) · Neuromyelitis Optica Spectrum Disorders (NMOSD)
NCT07420296 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2026-12-31 · Roche · Colorectal Cancer
NCT03303495 · CT.gov ↗
What to watch
LisaftoclaxPhase 3
Est. primary completion 2026-12-31 · Ascentage Pharma Group Inc. · CLL/SLL
NCT06104566 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2026-12-31 · AstraZeneca + Ono Pharmaceutical · Pediatric Hereditary Kidney Diseases
NCT06890143 · CT.gov ↗
What to watch
HRS-9190Phase 3
Est. primary completion 2026-12-31 · Jiangsu Hengrui Pharmaceuticals · Neuromuscular Blockade
NCT07746726 · CT.gov ↗
What to watch
January 2027 (66)
AzetukalnerPhase 3
Est. primary completion 2027-01 · Xenon Pharmaceuticals · Major Depressive Disorder
NCT06922110 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-01 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · Polymyalgia Rheumatica
NCT05533164 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2027-01 · AbbVie · Atopic Dermatitis
NCT06701331 · CT.gov ↗
What to watch
VormatriginePhase 3
Est. primary completion 2027-01 · Praxis Precision Medicines, Inc. · Epilepsy, Focal Onset Seizures
NCT07505004 · CT.gov ↗
What to watch
Sotagliflozin (Inpefa) · InpefaPhase 3
Est. primary completion 2027-01 · Lexicon Pharmaceuticals + Viatris · Hypertrophic Cardiomyopathy
NCT06481891 · CT.gov ↗
What to watch
setrusumabPhase 3
Est. primary completion 2027-01 · Mereo BioPharma + Ultragenyx Pharmaceutical Inc. · Osteogenesis Imperfecta
NCT06636071 · CT.gov ↗
What to watch
crisaborole · EucrisaPhase 3
Est. primary completion 2027-01 · Pfizer · Atopic Dermatitis
NCT07162896 · CT.gov ↗
What to watch
RSS0393Phase 3
Est. primary completion 2027-01 · Jiangsu Hengrui Pharmaceuticals + Reistone Biopharma · Psoriasis
NCT07543224 · CT.gov ↗
What to watch
IvonescimabPhase 3
Est. primary completion 2027-01 · Akeso + Summit Therapeutics · Head and Neck Squamous Cell Carcinoma
NCT06601335 · CT.gov ↗
What to watch
LigufalimabPhase 3
Est. primary completion 2027-01 · Akeso · Head and Neck Squamous Cell Carcinoma
NCT06601335 · CT.gov ↗
What to watch
Semaglutide (Ozempic) · OzempicPhase 3
Est. primary completion 2027-01 · Novo Nordisk · Diabetes Type 1
NCT06894784 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2027-01 · Boehringer Ingelheim + Eli Lilly · Diabetes Type 1
NCT06894784 · CT.gov ↗
What to watch
Ticagrelor · BrilintaPhase 3
Est. primary completion 2027-01 · AstraZeneca · Chronic Coronary Disease
NCT05997693 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2027-01 · AstraZeneca + Ono Pharmaceutical · STEMI - ST Elevation Myocardial Infarction, Epicardial Fat
NCT07297589 · CT.gov ↗
What to watch
Lacosamide · VimpatPhase 3
Est. primary completion 2027-01 · UCB · Bipolar Affective Disorder
NCT07412132 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-01-01 · Merck & Co. · Urothelial Carcinoma
NCT03244384 · CT.gov ↗
What to watch
LaroprovstatPhase 3
Est. primary completion 2027-01-04 · AstraZeneca · Atherosclerotic Cardiovascular Disease
NCT07000136 · CT.gov ↗
What to watch
sonelokimabPhase 3
Est. primary completion 2027-01-04 · MoonLake Immunotherapeutics · Psoriatic Arthritis
NCT06641089 · CT.gov ↗
What to watch
AnifrolumabPhase 3
Est. primary completion 2027-01-06 · AstraZeneca + MedImmune LLC · Systemic Sclerosis
NCT05925803 · CT.gov ↗
What to watch
Axitinib intravitreal implant (OTX-TKI)Phase 3
Est. primary completion 2027-01-08 · OCULAR THERAPEUTIX, INC · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
NCT06495918 · CT.gov ↗
What to watch
OleclumabPhase 3
Est. primary completion 2027-01-08 · MedImmune LLC · Non-Small Cell Lung Cancer
NCT05221840 · CT.gov ↗
What to watch
MonalizumabPhase 3
Est. primary completion 2027-01-08 · Innate Pharma + MedImmune LLC · Non-Small Cell Lung Cancer
NCT05221840 · CT.gov ↗
What to watch
Trastuzumab EmtansinePhase 3
Est. primary completion 2027-01-09 · Roche · HER2-Positive Breast Cancer, Breast Cancer
NCT07673029 · CT.gov ↗
What to watch
MezigdomidePhase 3
Est. primary completion 2027-01-10 · Bristol-Myers Squibb · Multiple Myeloma
NCT05519085 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2027-01-10 · Janssen + Takeda Pharmaceutical Company · Multiple Myeloma
NCT05519085 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2027-01-10 · · Relapsed or Refractory Multiple Myeloma
NCT05519085 · CT.gov ↗
What to watch
LaroprovstatPhase 3
Est. primary completion 2027-01-11 · AstraZeneca · Atherosclerotic Cardiovascular Disease
NCT07000123 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 3
Est. primary completion 2027-01-11 · AstraZeneca · Non-Small Cell Lung Cancer
NCT06417814 · CT.gov ↗
What to watch
Datopotamab DeruxtecanPhase 3
Est. primary completion 2027-01-11 · AstraZeneca + Daiichi Sankyo · Non-Small Cell Lung Cancer
NCT06417814 · CT.gov ↗
What to watch
pemetrexed · AlimtaPhase 3
Est. primary completion 2027-01-11 · Eli Lilly · Non-Small Cell Lung Cancer
NCT06417814 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-01-12 · Merck & Co. · Non-Small Cell Lung Cancer
NCT05609968 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2027-01-12 · Gilead Sciences · Non-Small Cell Lung Cancer
NCT05609968 · CT.gov ↗
What to watch
infliximab · RemicadePhase 3
Est. primary completion 2027-01-12 · Johnson & Johnson · Sarcoidosis
NCT05689879 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-01-12 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · Lymphoma, Large B-Cell, Diffuse
NCT06573645 · CT.gov ↗
What to watch
tezepelumab · TezspirePhase 3
Est. primary completion 2027-01-13 · Amgen + AstraZeneca · Chronic Rhinosinusitis With Nasal Polyps
NCT06706817 · CT.gov ↗
What to watch
IvonescimabPhase 3
Est. primary completion 2027-01-13 · Akeso + Summit Therapeutics · Metastatic Colorectal Cancer
NCT06951503 · CT.gov ↗
What to watch
Amdokitug (Yisaituo) · YisaituoPhase 3
Est. primary completion 2027-01-14 · Sunshine Guojian Pharmaceutical · Ankylosing Spondylitis
NCT07261644 · CT.gov ↗
What to watch
CemiplimabPhase 3
Est. primary completion 2027-01-15 · Regeneron Pharmaceuticals · Melanoma
NCT05608291 · CT.gov ↗
What to watch
FianlimabPhase 3
Est. primary completion 2027-01-15 · Regeneron Pharmaceuticals · Melanoma
NCT05608291 · CT.gov ↗
What to watch
Inclisiran · LeqvioPhase 3
Est. primary completion 2027-01-16 · Alnylam Pharmaceuticals + Novartis · Atherosclerotic Cardiovascular Disease
NCT07102628 · CT.gov ↗
What to watch
Alectinib · AlecensaPhase 3
Est. primary completion 2027-01-19 · Chugai Pharma + Roche · Non-Small Cell Lung Cancer
NCT05170204 · CT.gov ↗
What to watch
EntrectinibPhase 3
Est. primary completion 2027-01-19 · Chugai Pharma + Roche · Non-Small Cell Lung Cancer
NCT05170204 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3
Est. primary completion 2027-01-21 · Amgen · Obesity, Type 2 Diabetes
NCT06858878 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3
Est. primary completion 2027-01-21 · Amgen · Obesity, Type 2 Diabetes
NCT06858839 · CT.gov ↗
What to watch
Ublituximab · BriumviPhase 3
Est. primary completion 2027-01-21 · Neuraxpharm + TG THERAPEUTICS, INC. · Multiple Sclerosis
NCT05877963 · CT.gov ↗
What to watch
insulin icodec · AwiqliPhase 3
Est. primary completion 2027-01-25 · Novo Nordisk · Diabetes Mellitus, Type 1
NCT07076199 · CT.gov ↗
What to watch
Suzetrigine · JournavxPhase 3
Est. primary completion 2027-01-25 · Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
NCT06696443 · CT.gov ↗
What to watch
fluticasone furoate/umeclidinium/vilanterol · Trelegy ElliptaPhase 3
Est. primary completion 2027-01-26 · GlaxoSmithKline · Asthma
NCT05757102 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 3
Est. primary completion 2027-01-28 · Novartis · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT05038735 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-01-29 · Merck & Co. · Urothelial Carcinoma
NCT05911295 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3
Est. primary completion 2027-01-29 · Pfizer + RemeGen Co., Ltd. · Urothelial Carcinoma
NCT05911295 · CT.gov ↗
What to watch
ZiltivekimabPhase 3
Est. primary completion 2027-01-29 · Novo Nordisk · Cardiovascular Risk, Acute Myocardial Infarction (AMI)
NCT06118281 · CT.gov ↗
What to watch
Iptacopan · FabhaltaPhase 3
Est. primary completion 2027-01-29 · Novartis · C3G
NCT04817618 · CT.gov ↗
What to watch
afimkibartPhase 3
Est. primary completion 2027-01-30 · Pfizer + Roche · Ulcerative Colitis
NCT06589986 · CT.gov ↗
What to watch
Tamoxifen (Soltamox) · SoltamoxPhase 3
Est. primary completion 2027-01-30 · Mayne Pharma + Rosemont Pharmaceuticals · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT04906395 · CT.gov ↗
What to watch
AnastrozolePhase 3
Est. primary completion 2027-01-30 · ANI Pharmaceuticals, Inc. + AstraZeneca + Laboratoires Juvisé Pharmaceuticals · HR+/HER2- Metastatic Breast Cancer
NCT04906395 · CT.gov ↗
What to watch
LetrozolePhase 3
Est. primary completion 2027-01-30 · Novartis · HR+/HER2- Metastatic Breast Cancer
NCT04906395 · CT.gov ↗
What to watch
ExemestanePhase 3
Est. primary completion 2027-01-30 · Pfizer · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT04906395 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2027-01-31 · AbbVie + Roche · Acute T Lymphoblastic Leukemia (T-ALL)
NCT07541755 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-01-31 · Merck & Co. · Urinary Bladder Neoplasms
NCT04241185 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-01-31 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · Mantle Cell Lymphoma
NCT03267433 · CT.gov ↗
What to watch
Ticagrelor · BrilintaPhase 3
Est. primary completion 2027-01-31 · AstraZeneca · Intracranial Arteriosclerosis, Stroke
NCT05047172 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3
Est. primary completion 2027-01-31 · Angelini Pharma S.p.A. (A.C.R.A.F. S.p.A.) + Eurofarma Laboratorios + Hikma Pharmaceuticals PLC + Ono Pharmaceutical + SK Biopharmaceuticals Co., Ltd. · Epilepsy
NCT06579573 · CT.gov ↗
What to watch
Macitentan · OpsumitPhase 3
Est. primary completion 2027-01-31 · Johnson & Johnson · Hypertension, Pulmonary
NCT05179876 · CT.gov ↗
What to watch
Tadalafil · AdcircaPhase 3
Est. primary completion 2027-01-31 · Eli Lilly + Nippon Shinyaku + United Therapeutics · Hypertension, Pulmonary
NCT05179876 · CT.gov ↗
What to watch
RemimazolamPhase 3
Est. primary completion 2027-01-31 · Jiangsu Hengrui Pharmaceuticals · Remimazolam Besylate, Mechanically Ventilated ICU Patients, Sedation
NCT07596589 · CT.gov ↗
What to watch
February 2027 (45)
PembrolizumabPhase 3
Est. primary completion 2027-02 · Merck & Co. · Breast Cancer
NCT05382286 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2027-02 · Gilead Sciences · Breast Cancer
NCT05382286 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2027-02 · AbbVie + Roche · Acute Myeloid Leukemia
NCT05183035 · CT.gov ↗
What to watch
AzacitidinePhase 3
Est. primary completion 2027-02 · Bristol-Myers Squibb · Acute Myeloid Leukemia
NCT05183035 · CT.gov ↗
What to watch
Gemtuzumab OzogamicinPhase 3
Est. primary completion 2027-02 · Pfizer · Acute Myeloid Leukemia
NCT05183035 · CT.gov ↗
What to watch
Bosentan · TracleerPhase 3
Est. primary completion 2027-02 · Johnson & Johnson · Ischemic Optic Neuropathy
NCT02377271 · CT.gov ↗
What to watch
CT-P51Phase 3
Est. primary completion 2027-02 · Celltrion · Non-Small Cell Lung Cancer
NCT06939595 · CT.gov ↗
What to watch
stapokibartPhase 3
Est. primary completion 2027-02 · Aeira Pte. Ltd. + CSPC ZhongQi Pharmaceutical Technology Co., Ltd. + Keymed Biosciences · Atopic Dermatitis
NCT07106372 · CT.gov ↗
What to watch
difamilast · Moizerto / AdqueyPhase 3
Est. primary completion 2027-02 · Acrotech Biopharma + Otsuka Holdings · Atopic Dermatitis
NCT07184645 · CT.gov ↗
What to watch
CT-P53Phase 3
Est. primary completion 2027-02 · Celltrion · Multiple Sclerosis
NCT05906992 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2027-02 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Type 2 Diabetes
NCT07060456 · CT.gov ↗
What to watch
Tabirafusp alfaPhase 3
Est. primary completion 2027-02 · Kodiak Sciences Inc. · Macular Edema Secondary to Inflammation
NCT06996080 · CT.gov ↗
What to watch
TQC3721Phase 3
Est. primary completion 2027-02 · AstraZeneca + Sino Biopharmaceutical · Chronic Obstructive Pulmonary Disease
NCT07464587 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2027-02 · · Obesity, Childhood, Insulin Resistance
NCT04578652 · CT.gov ↗
What to watch
ElismetrepPhase 3
Est. primary completion 2027-02 · TriGemX Bio · Migraine
NCT07645924 · CT.gov ↗
What to watch
orforglipron · FoundayoPhase 3
Est. primary completion 2027-02 · Chugai Pharma + Eli Lilly · Obesity
NCT06672549 · CT.gov ↗
What to watch
CarisbamatePhase 3
Est. primary completion 2027-02 · SK Biopharmaceuticals Co., Ltd. · Epilepsy
NCT05219617 · CT.gov ↗
What to watch
LetrozolePhase 3
Est. primary completion 2027-02-01 · Novartis · Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma …
NCT04095364 · CT.gov ↗
What to watch
ApatinibPhase 3
Est. primary completion 2027-02-01 · Advenchen Laboratories + Elevar Therapeutics, Inc. + HLB Life Science + Jiangsu Hengrui Pharmaceuticals · Advanced Breast Cancer, HR+/HER2- Breast Cancer
NCT06447623 · CT.gov ↗
What to watch
Fulvestrant · FaslodexPhase 3
Est. primary completion 2027-02-01 · AstraZeneca · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT06447623 · CT.gov ↗
What to watch
Montelukast (Singulair)Phase 3
Est. primary completion 2027-02-01 · Organon · Myocardial Infarction (MI)
NCT07320625 · CT.gov ↗
What to watch
Levosimendan · SimdaxPhase 3
Est. primary completion 2027-02-03 · Orion Corporation + Tenax Therapeutics · Cardiogenic Shock
NCT04020263 · CT.gov ↗
What to watch
teduglutide (Gattex) · GattexPhase 3
Est. primary completion 2027-02-10 · Takeda Pharmaceutical Company · Short Bowel Syndrome
NCT06973304 · CT.gov ↗
What to watch
guselkumab · TremfyaPhase 3
Est. primary completion 2027-02-10 · Johnson & Johnson · Ulcerative Colitis
NCT06260163 · CT.gov ↗
What to watch
icotrokinra · IcotydePhase 3
Est. primary completion 2027-02-10 · Johnson & Johnson + Protagonist Therapeutics · Psoriatic Arthritis
NCT06807424 · CT.gov ↗
What to watch
Tirzepatide (Zepbound) · ZepboundPhase 3
Est. primary completion 2027-02-14 · Eli Lilly · Obesity
NCT07481747 · CT.gov ↗
What to watch
AcalabrutinibPhase 3
Est. primary completion 2027-02-15 · AstraZeneca · Lymphoma, Mantle Cell
NCT02972840 · CT.gov ↗
What to watch
RepotrectinibPhase 3
Est. primary completion 2027-02-16 · Bristol-Myers Squibb + Zai Lab · Non-Small Cell Lung Cancer, ROS1-Positive Non-Small Cell Lung Cancer
NCT06140836 · CT.gov ↗
What to watch
HDM1002Phase 3
Est. primary completion 2027-02-16 · Hangzhou Zhongmei Huadong Pharmaceutical · Type 2 Diabetes
NCT07082114 · CT.gov ↗
What to watch
Zibotentan + DapagliflozinPhase 3
Est. primary completion 2027-02-18 · AstraZeneca · Chronic Kidney Disease
NCT06087835 · CT.gov ↗
What to watch
AND017Phase 3
Est. primary completion 2027-02-20 · Kind Pharmaceuticals · Chronic Kidney Disease
NCT07494409 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2027-02-20 · Cheplapharm Arzneimittel GmbH · Nasopharyngeal Carcinoma
NCT06239727 · CT.gov ↗
What to watch
CenvacibartPhase 3
Est. primary completion 2027-02-20 · Regeneron Pharmaceuticals · Venous Thromboembolism
NCT07015905 · CT.gov ↗
What to watch
AcalabrutinibPhase 3
Est. primary completion 2027-02-22 · AstraZeneca · Diffuse Large B-Cell Lymphoma
NCT04529772 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 3
Est. primary completion 2027-02-22 · AstraZeneca · Cancer
NCT05629234 · CT.gov ↗
What to watch
remibrutinibPhase 3
Est. primary completion 2027-02-22 · Novartis · Chronic Spontaneous Urticaria
NCT06868212 · CT.gov ↗
What to watch
AnifrolumabPhase 3
Est. primary completion 2027-02-23 · AstraZeneca + MedImmune LLC · Systemic Lupus Erythematosus
NCT05138133 · CT.gov ↗
What to watch
Suzetrigine · JournavxPhase 3
Est. primary completion 2027-02-23 · Vertex Pharmaceuticals · Total Knee Replacement Surgery, Post-operative Pain
NCT07548385 · CT.gov ↗
What to watch
IncobotulinumtoxinA (Xeomin) · XeominPhase 3
Est. primary completion 2027-02-24 · Merz Pharmaceuticals · Migraine
NCT05598723 · CT.gov ↗
What to watch
Abemaciclib · VerzenioPhase 3
Est. primary completion 2027-02-25 · Eli Lilly · Breast Cancer
NCT06341621 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 3
Est. primary completion 2027-02-26 · Novartis · Breast Cancer
NCT04208178 · CT.gov ↗
What to watch
EverolimusPhase 3
Est. primary completion 2027-02-26 · Novartis · Epilepsy
NCT02962414 · CT.gov ↗
What to watch
Tenapanor (Ibsrela) · IbsrelaPhase 3
Est. primary completion 2027-02-26 · Ardelyx + Knight Therapeutics · Chronic Idiopathic Constipation (CIC)
NCT07382167 · CT.gov ↗
What to watch
MevrometostatPhase 3
Est. primary completion 2027-02-28 · Pfizer · Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT06551324 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2027-02-28 · · Intermittent Claudication
NCT05132439 · CT.gov ↗
What to watch
March 2027 (76)
IncobotulinumtoxinA (Xeomin) · XeominPhase 3
Est. primary completion 2027-03 · Merz Pharmaceuticals · Migraine
NCT07018713 · CT.gov ↗
What to watch
IncobotulinumtoxinA (Xeomin) · XeominPhase 3
Est. primary completion 2027-03 · Merz Pharmaceuticals · Migraine
NCT07018700 · CT.gov ↗
What to watch
EpirubicinPhase 3
Est. primary completion 2027-03 · Pfizer · Breast Cancer
NCT02455141 · CT.gov ↗
What to watch
risankizumab · SkyriziPhase 3
Est. primary completion 2027-03 · AbbVie + Boehringer Ingelheim · Crohn's Disease
NCT06063967 · CT.gov ↗
What to watch
Olezarsen · TryngolzaPhase 3
Est. primary completion 2027-03 · Ionis Pharmaceuticals + Swedish Orphan Biovitrum AB (publ) + Theratechnologies · Severe Hypertriglyceridemia, Hypertriglyceridemia
NCT05681351 · CT.gov ↗
What to watch
ribupatidePhase 3
Est. primary completion 2027-03 · Jiangsu Hengrui Pharmaceuticals + Kailera Therapeutics · Obesity
NCT07285902 · CT.gov ↗
What to watch
baricitinib · OlumiantPhase 3
Est. primary completion 2027-03 · Eli Lilly + Incyte · Rheumatoid Arthritis
NCT04870203 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3
Est. primary completion 2027-03 · AbbVie · Systemic Lupus Erythematosus
NCT05843643 · CT.gov ↗
What to watch
Resmetirom · RezdiffraPhase 3
Est. primary completion 2027-03 · Madrigal Pharmaceuticals · MASH / NASH
NCT04951219 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-03 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · Severe Forms of Mucous Membrane Pemphigoid
NCT03295383 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-03 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · Diffuse Large B-Cell Lymphoma
NCT06929624 · CT.gov ↗
What to watch
SHR-A1912Phase 3
Est. primary completion 2027-03 · Jiangsu Hengrui Pharmaceuticals · Diffuse Large B-Cell Lymphoma
NCT06929624 · CT.gov ↗
What to watch
TelitaciceptPhase 3
Est. primary completion 2027-03 · RemeGen Co., Ltd. + Vor Bio · Generalized Myasthenia Gravis
NCT06456580 · CT.gov ↗
What to watch
SHR-1918Phase 3
Est. primary completion 2027-03 · Jiangsu Hengrui Pharmaceuticals · Hypertriglyceridemia
NCT07349615 · CT.gov ↗
What to watch
ZorevunersenPhase 3
Est. primary completion 2027-03 · Biogen + Stoke Therapeutics, Inc. · Dravet Syndrome
NCT06872125 · CT.gov ↗
What to watch
TQC3721Phase 3
Est. primary completion 2027-03 · AstraZeneca + Sino Biopharmaceutical · Chronic Obstructive Pulmonary Disease
NCT07147946 · CT.gov ↗
What to watch
AnakinraPhase 3
Est. primary completion 2027-03 · Swedish Orphan Biovitrum AB (publ) · Kawasaki Disease
NCT04656184 · CT.gov ↗
What to watch
QLM3003Phase 3
Est. primary completion 2027-03 · Qilu Pharmaceutical · Atopic Dermatitis
NCT06880276 · CT.gov ↗
What to watch
Axitinib intravitreal implant (OTX-TKI)Phase 3
Est. primary completion 2027-03 · OCULAR THERAPEUTIX, INC · Non-Proliferative Diabetic Retinopathy
NCT07235085 · CT.gov ↗
What to watch
Arsenic trioxide (QTX-2101)Phase 3
Est. primary completion 2027-03 · Quetzal Therapeutics · Acute Myeloid Leukemia
NCT07504458 · CT.gov ↗
What to watch
Cariprazine (Vraylar) · VraylarPhase 3
Est. primary completion 2027-03 · AbbVie + Gedeon Richter + Tanabe Pharma Corporation · Bipolar Disorder
NCT04777357 · CT.gov ↗
What to watch
RezvilutamidePhase 3
Est. primary completion 2027-03 · Jiangsu Hengrui Pharmaceuticals · Prostate Cancer
NCT07241416 · CT.gov ↗
What to watch
cagrilintide/semaglutide · CagriSemaPhase 3
Est. primary completion 2027-03-01 · Novo Nordisk · Obesity
NCT07011667 · CT.gov ↗
What to watch
UtidelonePhase 3
Est. primary completion 2027-03-01 · Beijing Biostar Pharmaceuticals · HR+/HER2- Metastatic Breast Cancer
NCT05172518 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2027-03-01 · Cheplapharm Arzneimittel GmbH · HR+/HER2- Metastatic Breast Cancer
NCT05172518 · CT.gov ↗
What to watch
DepemokimabPhase 3
Est. primary completion 2027-03-01 · GlaxoSmithKline · Asthma
NCT07671001 · CT.gov ↗
What to watch
RecaticimabPhase 3
Est. primary completion 2027-03-01 · Jiangsu Hengrui Pharmaceuticals · Stroke
NCT07002476 · CT.gov ↗
What to watch
AND017Phase 3
Est. primary completion 2027-03-01 · Kind Pharmaceuticals · Chronic Kidney Disease
NCT07487727 · CT.gov ↗
What to watch
DaratumumabPhase 3
Est. primary completion 2027-03-08 · Johnson & Johnson · Multiple Myeloma
NCT06952478 · CT.gov ↗
What to watch
CT-P44Phase 3
Est. primary completion 2027-03-08 · Celltrion · Multiple Myeloma
NCT06952478 · CT.gov ↗
What to watch
bimekizumab · BimzelxPhase 3
Est. primary completion 2027-03-09 · UCB · Psoriatic Arthritis, Psoriasis
NCT06506916 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2027-03-11 · Bristol-Myers Squibb + Ono Pharmaceutical · Renal Cell Carcinoma
NCT03873402 · CT.gov ↗
What to watch
IpilimumabPhase 3
Est. primary completion 2027-03-11 · Bristol-Myers Squibb + Ono Pharmaceutical · Renal Cell Carcinoma
NCT03873402 · CT.gov ↗
What to watch
setmelanotide · ImcivreePhase 3
Est. primary completion 2027-03-13 · Rhythm Pharmaceuticals · Obesity, Hypothalamic Obesity
NCT06760546 · CT.gov ↗
What to watch
RucaparibPhase 3
Est. primary completion 2027-03-15 · pharmaand · Prostate Cancer
NCT04455750 · CT.gov ↗
What to watch
Apadamtase alfa · AdzynmaPhase 3
Est. primary completion 2027-03-16 · Takeda Pharmaceutical Company · Thrombotic Thrombocytopenic Purpura (TTP)
NCT04683003 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2027-03-16 · Boehringer Ingelheim + Eli Lilly · Cardiogenic Shock
NCT05879276 · CT.gov ↗
What to watch
tofacitinib · XeljanzPhase 3
Est. primary completion 2027-03-17 · Pfizer · Ulcerative Colitis
NCT04624230 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-03-18 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · Marginal Zone Lymphoma
NCT04212013 · CT.gov ↗
What to watch
Olanzapine (Zyprexa) · ZyprexaPhase 3
Est. primary completion 2027-03-20 · Cheplapharm Arzneimittel GmbH + Eli Lilly · Advanced Cancer, Olanzapine, Progression Free Survival
NCT06338683 · CT.gov ↗
What to watch
Roflumilast (Daliresp) · DalirespPhase 3
Est. primary completion 2027-03-20 · AstraZeneca · Depressive Disorder, Major
NCT06860958 · CT.gov ↗
What to watch
CemiplimabPhase 3
Est. primary completion 2027-03-22 · Regeneron Pharmaceuticals · Melanoma
NCT06246916 · CT.gov ↗
What to watch
FianlimabPhase 3
Est. primary completion 2027-03-22 · Regeneron Pharmaceuticals · Melanoma
NCT06246916 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2027-03-23 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · HR+/HER2- Breast Cancer
NCT06977893 · CT.gov ↗
What to watch
Fitusiran · QfitliaPhase 3
Est. primary completion 2027-03-25 · Alnylam Pharmaceuticals + Sanofi · Hemophilia
NCT05662319 · CT.gov ↗
What to watch
guselkumab · TremfyaPhase 3
Est. primary completion 2027-03-25 · Johnson & Johnson · Crohn's Disease
NCT05347095 · CT.gov ↗
What to watch
VAY736Phase 3
Est. primary completion 2027-03-26 · Novartis · Systemic Lupus Erythematosus
NCT05639114 · CT.gov ↗
What to watch
Osimertinib · TagrissoPhase 3
Est. primary completion 2027-03-26 · AstraZeneca · Non-Small Cell Lung Cancer
NCT06380348 · CT.gov ↗
What to watch
BecotatugPhase 3
Est. primary completion 2027-03-26 · Shanghai JMT-Bio · Non-Small Cell Lung Cancer
NCT06380348 · CT.gov ↗
What to watch
Eptinezumab (Vyepti) · VyeptiPhase 3
Est. primary completion 2027-03-26 · H. Lundbeck · Migraine
NCT04965675 · CT.gov ↗
What to watch
PertuzumabPhase 3
Est. primary completion 2027-03-28 · Roche · Solid Tumors
NCT02320435 · CT.gov ↗
What to watch
Staccato AlprazolamPhase 3
Est. primary completion 2027-03-29 · Nova Pneuma Inc. + UCB · Epilepsy
NCT05077904 · CT.gov ↗
What to watch
Sacituzumab GovitecanPhase 3
Est. primary completion 2027-03-30 · Gilead Sciences · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT04595565 · CT.gov ↗
What to watch
CapecitabinePhase 3
Est. primary completion 2027-03-30 · Cheplapharm Arzneimittel GmbH · HR+/HER2- Metastatic Breast Cancer
NCT04595565 · CT.gov ↗
What to watch
olatorepatidePhase 3
Est. primary completion 2027-03-30 · Hansoh Pharmaceutical Group + Regeneron Pharmaceuticals · Type 2 Diabetes
NCT07156500 · CT.gov ↗
What to watch
olatorepatidePhase 3
Est. primary completion 2027-03-30 · Hansoh Pharmaceutical Group + Regeneron Pharmaceuticals · Type 2 Diabetes
NCT07156539 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3
Est. primary completion 2027-03-30 · China Medical System + Nippon Shinyaku + Pfizer + Pharmacosmos · Iron Deficiency Anemia
NCT05462704 · CT.gov ↗
What to watch
BinimetinibPhase 3
Est. primary completion 2027-03-31 · Ono Pharmaceutical + Pfizer + Pierre Fabre Medicament · Melanoma
NCT05270044 · CT.gov ↗
What to watch
EncorafenibPhase 3
Est. primary completion 2027-03-31 · Ono Pharmaceutical + Pfizer + Pierre Fabre Medicament · Melanoma
NCT05270044 · CT.gov ↗
What to watch
ToripalimabPhase 3
Est. primary completion 2027-03-31 · Coherus BioSciences, Inc. + Shanghai Junshi Bioscience · Gastric or Esophagogastric Junction Adenocarcinoma
NCT05180734 · CT.gov ↗
What to watch
AtezolizumabPhase 3
Est. primary completion 2027-03-31 · Chugai Pharma + Roche · Breast Cancer
NCT04873362 · CT.gov ↗
What to watch
GemcitabinePhase 3
Est. primary completion 2027-03-31 · Eli Lilly · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma …
NCT03533582 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb + Ono Pharmaceutical · Non-Small Cell Lung Cancer
NCT03391869 · CT.gov ↗
What to watch
IpilimumabPhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb + Ono Pharmaceutical · Non-Small Cell Lung Cancer
NCT03391869 · CT.gov ↗
What to watch
PF-06651600Phase 3
Est. primary completion 2027-03-31 · Pfizer · Vitiligo
NCT06163326 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb + Ono Pharmaceutical · Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma …
NCT04444921 · CT.gov ↗
What to watch
HS-20137Phase 3
Est. primary completion 2027-03-31 · Hansoh Pharmaceutical Group + Qyuns Therapeutics · Psoriasis
NCT06844799 · CT.gov ↗
What to watch
RegorafenibPhase 3
Est. primary completion 2027-03-31 · Bayer · Colorectal Cancer
NCT05794971 · CT.gov ↗
What to watch
Liraglutide (Victoza) · VictozaPhase 3
Est. primary completion 2027-03-31 · Novo Nordisk · Delirium, Postoperative
NCT06361238 · CT.gov ↗
What to watch
metformin · GlucophagePhase 3
Est. primary completion 2027-03-31 · · Obesity and Cardiovascular Risk, Insulin Resistance, Obesity (Body Mass Index >30 kg/m2)
NCT07297290 · CT.gov ↗
What to watch
Neovasculgen · NeovasculgenPhase 3
Est. primary completion 2027-03-31 · Artgen Biotech · Ulcer Foot, Mellitus Diabetes
NCT07391319 · CT.gov ↗
What to watch
PomalidomidePhase 3
Est. primary completion 2027-03-31 · Bristol-Myers Squibb · Multiple Myeloma
NCT06508983 · CT.gov ↗
What to watch
SanritatugPhase 3
Est. primary completion 2027-03-31 · Hangzhou Sumgen Biotech Co., Ltd. · Multiple Myeloma
NCT06508983 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2027-03-31 · · Relapsed/Refractory Multiple Myeloma
NCT06508983 · CT.gov ↗
What to watch
OlverembatinibPhase 3
Est. primary completion 2027-03-31 · Ascentage Pharma Group Inc. + Innovent Biologics · GIST
NCT06640361 · CT.gov ↗
What to watch
Suzetrigine · JournavxPhase 3
Est. primary completion 2027-03-31 · Vertex Pharmaceuticals · Opioid Consumption, Postoperative, Multimodal Analgesia, Ureteroscopy, Ureteral Stents, Ureteral Stent-Related Symptoms
NCT07654296 · CT.gov ↗
What to watch
April 2027 (74)
N-acetylcysteinePhase 3
Est. primary completion 2027-04 · Apotex Inc. + Phebra Pty Ltd · Thoracic Surgery, Atrial Fibrillation in High Risk Patients
NCT02750319 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2027-04 · Roche · Ovarian Cancer
NCT05445778 · CT.gov ↗
What to watch
Mirvetuximab soravtansine · ElaherePhase 3
Est. primary completion 2027-04 · AbbVie + Takeda Pharmaceutical Company · Ovarian Cancer
NCT05445778 · CT.gov ↗
What to watch
Docetaxel · TaxoterePhase 3
Est. primary completion 2027-04 · Sanofi · HR+/HER2- Metastatic Breast Cancer
NCT04540692 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3
Est. primary completion 2027-04 · Merck & Co. + Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Breast Cancer
NCT06279364 · CT.gov ↗
What to watch
cadisegliatinPhase 3
Est. primary completion 2027-04 · G42 Healthcare + vTv Therapeutics · Type 1 Diabetes
NCT06334133 · CT.gov ↗
What to watch
Sacubitril/valsartan · EntrestoPhase 3
Est. primary completion 2027-04 · Novartis + Otsuka Holdings · Heart Failure
NCT06712030 · CT.gov ↗
What to watch
Vadadustat · VafseoPhase 3
Est. primary completion 2027-04 · Akebia Therapeutics + Medice + Tanabe Pharma Corporation · Chronic Kidney Disease
NCT07565701 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2027-04 · AstraZeneca + Ono Pharmaceutical · Diabetes Mellitus, Atrial Fibrillation
NCT05174052 · CT.gov ↗
What to watch
Tabirafusp alfaPhase 3
Est. primary completion 2027-04 · Kodiak Sciences Inc. · Macular Edema Secondary to Inflammation
NCT06990399 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 3
Est. primary completion 2027-04 · Chugai Pharma + Roche · Sickle Cell Disease, Acute Chest Syndrome
NCT06818266 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2027-04 · Janssen + Takeda Pharmaceutical Company · Multiple Myeloma
NCT05558319 · CT.gov ↗
What to watch
LenalidomidePhase 3
Est. primary completion 2027-04 · Bristol-Myers Squibb + Celgene Corporation · Multiple Myeloma
NCT05558319 · CT.gov ↗
What to watch
IsatuximabPhase 3
Est. primary completion 2027-04 · Sanofi · Multiple Myeloma
NCT05558319 · CT.gov ↗
What to watch
Iberdomide · ZenbexusPhase 3
Est. primary completion 2027-04 · Bristol-Myers Squibb · Multiple Myeloma
NCT05558319 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2027-04 · · Newly Diagnosed Multiple Myeloma
NCT05558319 · CT.gov ↗
What to watch
Pitolisant (Wakix) · WakixPhase 3
Est. primary completion 2027-04 · Bioprojet + Harmony Biosciences + Viatris · Prader-Willi Syndrome
NCT06366464 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-04 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · Acute Demyelinating Syndrome, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05545384 · CT.gov ↗
What to watch
GS101Phase 3
Est. primary completion 2027-04 · Jiangsu Genscend Biopharmaceutical · Atopic Dermatitis
NCT07386743 · CT.gov ↗
What to watch
Clemizole (EPX-100)Phase 3
Est. primary completion 2027-04 · Harmony Biosciences · Epilepsy, Dravet Syndrome
NCT04462770 · CT.gov ↗
What to watch
NivolumabPhase 3
Est. primary completion 2027-04 · Bristol-Myers Squibb + Ono Pharmaceutical · Melanoma
NCT07221734 · CT.gov ↗
What to watch
AzetukalnerPhase 3
Est. primary completion 2027-04 · Xenon Pharmaceuticals · Epilepsy, Primary Generalized Tonic-Clonic Seizures
NCT05667142 · CT.gov ↗
What to watch
Abemaciclib · VerzenioPhase 3
Est. primary completion 2027-04 · Eli Lilly · HR+/HER2- Metastatic Breast Cancer, Breast Cancer
NCT05696626 · CT.gov ↗
What to watch
Zoledronic acidPhase 3
Est. primary completion 2027-04 · Novartis · Giant Cell Tumor of Bone
NCT03295981 · CT.gov ↗
What to watch
Docetaxel · TaxoterePhase 3
Est. primary completion 2027-04-01 · Sanofi · Prostate Cancer
NCT03574571 · CT.gov ↗
What to watch
AnastrozolePhase 3
Est. primary completion 2027-04-01 · ANI Pharmaceuticals, Inc. + AstraZeneca + Laboratoires Juvisé Pharmaceuticals · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma …
NCT01953588 · CT.gov ↗
What to watch
Fulvestrant · FaslodexPhase 3
Est. primary completion 2027-04-01 · AstraZeneca · Breast Cancer
NCT01953588 · CT.gov ↗
What to watch
NaltrexonePhase 3
Est. primary completion 2027-04-01 · · Alcohol Use Disorder (AUD)
NCT07433413 · CT.gov ↗
What to watch
BevacizumabPhase 3
Est. primary completion 2027-04-01 · Roche · Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
NCT05271240 · CT.gov ↗
What to watch
TemozolomidePhase 3
Est. primary completion 2027-04-01 · Merck & Co. · Glioblastoma, Glioma
NCT05271240 · CT.gov ↗
What to watch
BortezomibPhase 3
Est. primary completion 2027-04-05 · Janssen + Takeda Pharmaceutical Company · Multiple Myeloma
NCT03319667 · CT.gov ↗
What to watch
LenalidomidePhase 3
Est. primary completion 2027-04-05 · Bristol-Myers Squibb + Celgene Corporation · Multiple Myeloma
NCT03319667 · CT.gov ↗
What to watch
IsatuximabPhase 3
Est. primary completion 2027-04-05 · Sanofi · Multiple Myeloma
NCT03319667 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2027-04-05 · · Plasma Cell Myeloma
NCT03319667 · CT.gov ↗
What to watch
Lumateperone · CaplytaPhase 3
Est. primary completion 2027-04-05 · Intra-Cellular Therapies + Johnson & Johnson · Major Depressive Disorder
NCT05850689 · CT.gov ↗
What to watch
OlaparibPhase 3
Est. primary completion 2027-04-06 · AstraZeneca + Merck & Co. · HR+/HER2- Metastatic Breast Cancer, Ovarian Cancer, Breast Cancer
NCT04421963 · CT.gov ↗
What to watch
Elexacaftor / tezacaftor / ivacaftor · TrikaftaPhase 3
Est. primary completion 2027-04-06 · Vertex Pharmaceuticals · Cystic Fibrosis
NCT05331183 · CT.gov ↗
What to watch
Suzetrigine · JournavxPhase 3
Est. primary completion 2027-04-06 · Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
NCT07231419 · CT.gov ↗
What to watch
DexamethasonePhase 3
Est. primary completion 2027-04-08 · · Primary Immune Thrombocytopenia (ITP)
NCT07559331 · CT.gov ↗
What to watch
Finerenone · KerendiaPhase 3
Est. primary completion 2027-04-10 · Bayer · Chronic Kidney Disease
NCT05196035 · CT.gov ↗
What to watch
VAY736Phase 3
Est. primary completion 2027-04-12 · Novartis · Systemic Lupus Erythematosus
NCT05624749 · CT.gov ↗
What to watch
Nerandomilast (Jascayd) · JascaydPhase 3
Est. primary completion 2027-04-15 · Boehringer Ingelheim · Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
NCT06806592 · CT.gov ↗
What to watch
TislelizumabPhase 3
Est. primary completion 2027-04-15 · BeOne Medicines · Bladder Cancer
NCT06364904 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2027-04-16 · Boehringer Ingelheim + Eli Lilly · Chronic Kidney Disease
NCT07107945 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3
Est. primary completion 2027-04-16 · AstraZeneca + Ono Pharmaceutical · Heart Failure
NCT06307652 · CT.gov ↗
What to watch
BalcinrenonePhase 3
Est. primary completion 2027-04-16 · AstraZeneca · Heart Failure
NCT06307652 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3
Est. primary completion 2027-04-16 · Biogen + Chugai Pharma + Roche + Zenyaku Kogyo · ANCA Associated Vasculitis (AAV)
NCT07168161 · CT.gov ↗
What to watch
Enasidenib · IdhifaPhase 3
Est. primary completion 2027-04-17 · Bristol-Myers Squibb · Acute Myeloid Leukemia
NCT03839771 · CT.gov ↗
What to watch
Ivosidenib · TibsovoPhase 3
Est. primary completion 2027-04-17 · Servier · Acute Myeloid Leukemia
NCT03839771 · CT.gov ↗
What to watch
Saroglitazar · LipaglynPhase 3
Est. primary completion 2027-04-18 · Zydus Lifesciences · Primary Biliary Cholangitis
NCT06427395 · CT.gov ↗
What to watch
ABP 692Phase 3
Est. primary completion 2027-04-19 · Amgen · Multiple Sclerosis
NCT06700343 · CT.gov ↗
What to watch
Camizestrant · EtcamahPhase 3
Est. primary completion 2027-04-20 · AstraZeneca · Breast Cancer
NCT05774951 · CT.gov ↗
What to watch
tocilizumab · Actemra / RoActemraPhase 3
Est. primary completion 2027-04-20 · Chugai Pharma + Roche · Ischemic Stroke
NCT07509645 · CT.gov ↗
What to watch
lebrikizumab · EbglyssPhase 3
Est. primary completion 2027-04-25 · Almirall + Eli Lilly · Atopic Dermatitis
NCT06526182 · CT.gov ↗
What to watch
ORMD-0801Phase 3
Est. primary completion 2027-04-25 · Lifeward Ltd. · Type 2 Diabetes
NCT06731075 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3
Est. primary completion 2027-04-27 · Amgen · Obesity
NCT06987695 · CT.gov ↗
What to watch
Nerandomilast (Jascayd) · JascaydPhase 3
Est. primary completion 2027-04-28 · Boehringer Ingelheim · Idiopathic Pulmonary Fibrosis
NCT06238622 · CT.gov ↗
What to watch
SYHX1901Phase 3
Est. primary completion 2027-04-28 · CSPC Ouyi Pharmaceutical Co. + CSPC Pharmaceutical Group · Psoriasis
NCT06943950 · CT.gov ↗
What to watch
BGM0504Phase 3
Est. primary completion 2027-04-30 · BrightGene Bio-Medical Technology + China Resources Sanjiu Medical & Pharmaceutical · Type 2 Diabetes
NCT07064486 · CT.gov ↗
What to watch
VenetoclaxPhase 3
Est. primary completion 2027-04-30 · AbbVie + Roche · Chronic Lymphocytic Leukemia
NCT03836261 · CT.gov ↗
What to watch
AcalabrutinibPhase 3
Est. primary completion 2027-04-30 · AstraZeneca · Chronic Lymphocytic Leukemia
NCT03836261 · CT.gov ↗
ObinutuzumabPhase 3
Est. primary completion 2027-04-30 · Roche · Chronic Lymphocytic Leukemia
NCT03836261 · CT.gov ↗
Iptacopan · FabhaltaPhase 3
Est. primary completion 2027-04-30 · Novartis · Generalized Myasthenia Gravis
NCT06517758 · CT.gov ↗
What to watch
LuvometinibPhase 3
Est. primary completion 2027-04-30 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Glioma
NCT07004075 · CT.gov ↗
What to watch
TVAX-008Phase 3
Est. primary completion 2027-04-30 · Grand Theravac Life Science (Nanjing) Co., Ltd. · Chronic Hepatitis B
NCT07282249 · CT.gov ↗
What to watch
PembrolizumabPhase 3
Est. primary completion 2027-04-30 · Merck & Co. · Head and Neck Squamous Cell Carcinoma
NCT06102395 · CT.gov ↗
What to watch
Docetaxel · TaxoterePhase 3
Est. primary completion 2027-04-30 · Sanofi · Head and Neck Squamous Cell Carcinoma
NCT06102395 · CT.gov ↗
What to watch
Nab-paclitaxelPhase 3
Est. primary completion 2027-04-30 · Bristol-Myers Squibb · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
NCT06102395 · CT.gov ↗
What to watch
BAT5906Phase 3
Est. primary completion 2027-04-30 · Bio-Thera Solutions · Diabetic Macular Edema (DME)
NCT07515079 · CT.gov ↗
What to watch
Semaglutide (Ozempic) · OzempicPhase 3
Est. primary completion 2027-04-30 · Novo Nordisk · Klinefelter Syndrome
NCT05586802 · CT.gov ↗
What to watch
AnastrozolePhase 3
Est. primary completion 2027-04-30 · ANI Pharmaceuticals, Inc. + AstraZeneca + Laboratoires Juvisé Pharmaceuticals · Klinefelter Syndrome
NCT05586802 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3
Est. primary completion 2027-04-30 · China Medical System + Nippon Shinyaku + Pfizer + Pharmacosmos · Iron Deficiency Anemia
NCT05179226 · CT.gov ↗
What to watch
Ruxolitinib (Opzelura) · OpzeluraPhase 3
Est. primary completion 2027-04-30 · Incyte + Maruho · Vitiligo
NCT06804811 · CT.gov ↗
What to watch
Empagliflozin · JardiancePhase 3
Est. primary completion 2027-04-30 · Boehringer Ingelheim + Eli Lilly · Heart Failure
NCT07038356 · CT.gov ↗
What to watch

Upcoming earnings

Expected report dates from the sourced earnings calendar (US-listed companies only; no forward date is sourced for foreign-only listings). Dates can and do move before the report.

  • 2026-11-23BioLineRx Ltd.period ending 2026-09-30
  • 2026-11-23Matinas BioPharmaperiod ending 2026-09-30
  • 2026-11-24Anavex Life Sciencesperiod ending 2026-09-30
  • 2026-11-25Galmed Pharmaceuticals Ltd.period ending 2026-09-30
  • 2026-11-25Lexaria Bioscienceperiod ending 2026-08-31
  • 2026-12-02Attovia Therapeuticsperiod ending 2026-09-30
  • 2026-12-03MapLight Therapeuticsperiod ending 2026-09-30
  • 2026-12-08Alzamend Neuroperiod ending 2026-10-31
  • 2026-12-10Evommuneperiod ending 2026-09-30
  • 2026-12-16Veru Inc.period ending 2026-09-30
  • 2026-12-18BlossomHill Therapeuticsperiod ending 2026-09-30
  • 2026-12-21Abivaxperiod ending 2026-09-30After quarter end. No owned study is estimated to reach primary completion inside this reporting period. Falling just after quarter end: obefazimod, phase 2, NCT06456593 (estimated 2026-12-01).About these dates. This date is the registry's estimated primary completion, not a confirmed readout date.
  • 2026-12-22Bright Minds Biosciences Inc.period ending 2026-09-30After quarter end. No owned study is estimated to reach primary completion inside this reporting period. Falling just after quarter end: BMB-101, phase 2, NCT07266324 (estimated 2026-11-01).About these dates. This date is the registry's estimated primary completion, not a confirmed readout date.
  • 2027-01-11Alpha Compute Corpperiod ending 2026-12-31
  • 2027-01-11Alpha Compute Corpperiod ending 2026-09-30
  • 2027-01-28Rocheperiod ending 2026-12-31Clinical milestones in this period. Owned studies estimated to reach primary completion inside this reporting period: Atezolizumab, phase 3, NCT03148418 (estimated 2026-11-30); Bevacizumab, phase 3, NCT05281471 (estimated 2026-12-01) and NCT05654454 (estimated 2026-12-01).About these dates. This date is the registry's estimated primary completion, not a confirmed readout date.
  • 2027-02-02Pfizerperiod ending 2026-12-31Clinical milestones in this period. Owned studies estimated to reach primary completion inside this reporting period: Rimegepant (Nurtec ODT), phase 3, NCT06641466 (estimated 2026-11-29); Binimetinib, phase 3, NCT03803553 (estimated 2026-12-01); Encorafenib, phase 3, NCT03803553 (estimated 2026-12-01).About these dates. This date is the registry's estimated primary completion, not a confirmed readout date.

Educational data tool. Earnings dates cover US-listed companies only; no forward earnings date is sourced for foreign-only listings.